Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis

Tim Spelman(Peter Doherty Institute), Jan Lycke(Sahlgrenska University Hospital), Melinda Magyari(University of Copenhagen), Anders Svenningsson(Karolinska Institutet), Matthias Kant(Sygehus Sønderjylland), Jan Hillert, Peter Vestergaard Rasmussen(Aarhus University Hospital), Fredrik Piehl(Karolinska University Hospital), Hanna Joensen(Rigshospitalet), Finn Sellebjerg(Danish Multiple Sclerosis Center)
JAMA Neurology
August 16, 2021
10.1001/jamaneurol.2021.2738
Cited by 237

Related Papers

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k
Multiple Sclerosis Severity Score
|Neurology|2005|957
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|587
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554